Commentary on Abstract #2833 and #4812

Publication
Article
OncologyONCOLOGY Vol 14 No 3
Volume 14
Issue 3

In general, results with autologous stem-cell transplantation for patients with follicular NHL have been disappointing, without the evidence for cure observed in patients with large B-cell NHL (Rohatiner et al: J Clin Oncol 12:1177-1184, 1994;

In general, results with autologous stem-cell transplantation for patients with follicular NHL have been disappointing, without the evidence for cure observed in patients with large B-cell NHL (Rohatiner et al: J Clin Oncol 12:1177-1184, 1994; Freedman and Nadler: J Clin Oncol 11:1841-1843, 1993; Freedman et al: Blood 94:3325-3333, 1999). A major problem has been the high rate of recurrence, related, in part, to reinfusion of tumor cells.

In vitro purging with monoclonal antibodies and complement can render the stem cells PCR negative, and patients who become persistently PCR negative may experience a prolongation of disease-free survival (Freedman et al: Blood 94:3325-3333, 1999). Rituximab administered during stem-cell mobilization has been evaluated as a method of in vivo purging to reduce tumor load.

Flinn et al (abstract #2833) described their experience with 51 patients who had a variety of histologies of low-grade NHL and mantle cell lymphoma. A single infusion of rituximab was administered during mobilization, and one or four infusions were given following transplant as an adjuvant. Mobilization was successful in all but five patients, with no additional toxicity noted. No outcome data are yet available.

Buckstein et al (abstract #4812) also administered rituximab both as an in vivo purge and as adjuvant therapy following autologous transplantation. All 14 patients underwent successful stem-cell harvesting. Despite the fact that six of the seven stem-cell products remained positive, all patients subsequently became PCR negative.

Whether there are longer-term consequences of rituximab in vivo purging, such as late infections or graft failure, remains to be determined by longer follow-up. Phase III trials are being planned to evaluate the role of in vivo purging with rituximab.

Articles in this issue

Comparative Economic Analysis of the Treatment of Relapsed Low-Grade B-Cell Non-Hodgkin’s Lymphoma (NHL) in France Using CHOP, Fludarabine, or Rituximab
FHIT Gene, Smoking, and Cervical Cancer
Final Report on the Safety and Efficacy of Retreatment With Rituximab for Patients With Non-Hodgkins Lymphoma
Prospective, Randomized, Controlled Study of Zevalin Radioimmunotherapy Compared to Rituximab Immunotherapy for B-Cell, Non-Hodgkins Lymphoma: Interim Results
IOM Medical Error Estimates Questioned, But Legislation Considered
Less Toxic Therapies for Hodgkin’s Disease May Reduce Secondary Cancers
Preserving Fertility in Young Women With Ovarian Cancer Does Not Decrease Survival
Iodine-131 Tositumomab for Patients With Transformed, Low-Grade Non-Hodgkin’s Lymphoma: Overall Clinical Trial Experience
Survival Rates Significantly Worse For African-Americans With Endometrial Cancer
Rituximab Has Significant Activity in Patients With Chronic Lymphocytic Leukemia
Responders to Rituximab Show Continued Tumor Regression Over Time and a Progression-Free Survival That Correlates With Response Classification
PhRMA Criticizes FDA’s Proposed Rule on Antibiotic Approvals
Phase II Study of Rituximab in Combination With CHOP in Patients With Previously Untreated Intermediate- or High-Grade Non-Hodgkin’s Lymphoma
New Antibiotic Effective in Treating Gram-Positive Bacteremia
Reduced-Dose Zevalin Radioimmunotherapy for Relapsed or Refractory B-Cell Non-Hodgkin’s Lymphoma Patients With Preexisting Thrombocytopenia: Report of Interim Results of a Phase II Trial
Related Videos
Findings show no difference in overall survival between various treatments for metastatic RCC previously managed with immunotherapy and TKIs.
An epigenomic profiling approach may help pick up the entire tumor burden, thereby assisting with detecting sarcomatoid features in those with RCC.
A panel of 4 experts on multiple myeloma
A panel of 4 experts on multiple myeloma
Cesar Rodriguez, MD, and Frits van Rhee, MD, PhD
Investigators are assessing the use of IORT in patients with borderline resectable or unresectable pancreatic cancer as part of the phase 2 PACER trial.
2 KOLs are featured in this series
2 KOLs are featured in this series
A panel of 4 experts on multiple myeloma
A panel of 4 experts on multiple myeloma
Related Content